BioNexus Gene Lab Corp.
BioNexus Gene Lab Corp. (BGLC) PE Ratio — Current & Historical Data
Trailing twelve months (TTM) P/E, forward P/E, PEG, and annual PE history — from market prices and filings.
bglc · pe ratio · data through Dec 31, 2025
Core PE Ratio Metrics
Trailing 12 months · TTMThe price-to-earnings (P/E) ratio for BioNexus Gene Lab Corp. (BGLC) measures how much investors pay for each dollar of the company's trailing earnings. BGLC's current PE ratio of N/A is calculated by dividing its stock price of $2.19 by its TTM earnings per share of -$1.20.
Source: FMP · /ratios-ttm · /analyst-estimates · 2025-12-31
PE Ratio History
2016 – 2025 · Annual▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare (Annual)
Historical PE Range
Past 3 fiscal years · Front-end computedMinQ1 · 25%485.4x
MedianQ3 · 75%5518.8x
Max
At N/A, BGLC's current P/E is lower than in 0% of its annual fiscal year readings over the past 3 years — historically low.
Percentile calculated from annual fiscal year data points, not by trading day. Years where PE ≤ 0 or > 9,999 are excluded.
PE Ratio vs Peers
Medical - Diagnostics & Research · 6 peers · Annual PE| Company | Market Cap | PE (Annual) | vs Avg | EPS (TTM) |
|---|---|---|---|---|
BioNexus Gene Lab Corp.You BGLC | $4M | N/A | — | -$1.20 |
 Advanced Biomed Inc. Common Stock ADVB | $4M | N/A | — | -$0.09 |
 AEON Biopharma, Inc. AEON | $9M | N/A | — | -$3.95 |
 Aptorum Group Limited APM | $7M | N/A | — | -$0.19 |
 Check-Cap Ltd. CHEK | $11M | N/A | — | -$4.30 |
 Galecto, Inc. GLTO | $34M | N/A | — | -$143.51 |
 Lifeward Ltd. LFWD | $11M | N/A | — | -$1.72 |
* N/A — Company is not profitable (TTM) · excluded from industry average · ▸ FMP /stock-peers + /ratios?limit=1 · priceToEarningsRatio
Annual PE Ratio History
| Fiscal Year End | PE Ratio | EPS (TTM) | YoY Change | PE vs Max |
|---|---|---|---|---|
2025-12-31Latest FY2025 | — | $-1.61 | — | |
2024-12-31 FY2024 | — | $-0.90 | — | |
2023-12-31 FY2023 | — | $-1.53 | — | |
2022-12-31 FY2022 | — | $-0.25 | — | |
2021-12-31 FY2021 | 485.43x | $0.53 | +134.5% | |
2020-12-31 FY2020 | 207.02x | $1.28 | — | |
2019-12-31 FY2019 | — | $-0.34 | — | |
2018-12-31 FY2018 | 5518.83x | $0.05 | — | |
2017-12-31 FY2017 | — | $-0.20 | — | |
2016-12-31 FY2016 | — | $-0.00 | — |
▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare · Zero extra API
About PE Ratio & Methodology
The price-to-earnings (P/E) ratio for BioNexus Gene Lab Corp. (BGLC) measures how much investors pay for each dollar of the company's trailing earnings. BGLC's current PE ratio of N/A is calculated by dividing its stock price of $2.19 by its TTM earnings per share of -$1.20.
Frequently asked questions
BGLC pe ratio · 6 questionsBGLC's current PE ratio is N/A as of 2026-06-09, based on a stock price of $2.19 and TTM EPS of -$1.20. Data sourced from Financial Modeling Prep via BGLC's SEC 10-K and 10-Q filings.
▸ Source: FMP · /ratios-ttm · /ratios annual · /analyst-estimates · /stock-peers · BioNexus Gene Lab Corp. SEC 10-K & 10-Q filings · US GAAP · Updated: 2026-06-09